These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37420133)

  • 41. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study.
    Sayah FA; Bansback N; Bryan S; Ohinmaa A; Poissant L; Pullenayegum E; Xie F; Johnson JA
    Qual Life Res; 2016 Jul; 25(7):1679-85. PubMed ID: 26659899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preference heterogeneity in health valuation: a latent class analysis of the Peru EQ-5D-5L values.
    Karim S; Craig BM; Tejada RA; Augustovski F
    Health Qual Life Outcomes; 2023 Jan; 21(1):1. PubMed ID: 36593473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of four value sets derived using different TTO and DCE approaches: application to the new region-specific PBM, AP-7D.
    Shiroiwa T; Murata T; Morii Y; Hoshino E; Fukuda T
    Health Qual Life Outcomes; 2024 Feb; 22(1):16. PubMed ID: 38341575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
    Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
    Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
    Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing heuristic valuation processes between health state valuation from child and adult perspectives.
    Lipman SA; Reckers-Droog VT
    Eur J Health Econ; 2024 Feb; ():. PubMed ID: 38308719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimating Utility Values for Health States of DFU Patients Using EQ-5D-5L and cTTO.
    Arab-Zozani M; Safari H; Dori Z; Afshari S; Ameri H; Namiranian N; Hoseini E; Jafari A
    Int J Low Extrem Wounds; 2022 Mar; 21(1):41-49. PubMed ID: 33939495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the (not so) constant proportional trade-off in TTO.
    Attema AE; Brouwer WB
    Qual Life Res; 2010 May; 19(4):489-97. PubMed ID: 20151207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A threshold explanation for the lack of variation in negative composite time trade-off values.
    Roudijk B; Donders R; Stalmeier P
    Qual Life Res; 2022 Sep; 31(9):2753-2761. PubMed ID: 35622295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Testing "Pits" Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States?
    Liao M; Yang Z; Rand K; Luo N
    Value Health; 2024 May; ():. PubMed ID: 38795961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preference Elicitation Techniques Used in Valuing Children's Health-Related Quality-of-Life: A Systematic Review.
    Bailey C; Howell M; Raghunandan R; Salisbury A; Chen G; Coast J; Craig JC; Devlin NJ; Huynh E; Lancsar E; Mulhern BJ; Norman R; Petrou S; Ratcliffe J; Street DJ; Howard K; Viney R;
    Pharmacoeconomics; 2022 Jul; 40(7):663-698. PubMed ID: 35619044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient and public preferences for health states associated with AMD.
    Butt T; Dunbar HM; Morris S; Orr S; Rubin GS
    Optom Vis Sci; 2013 Aug; 90(8):855-60. PubMed ID: 23811607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exploring non-iterative time trade-off methods for valuation of EQ-5D-5L health states.
    Yang Z; Rand K; Stolk E; Busschbach J; Luo N
    Eur J Health Econ; 2023 Dec; ():. PubMed ID: 38104294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States.
    Prevolnik Rupel V; Ramos-Goñi JM; Ogorevc M; Kreimeier S; Ludwig K; Greiner W
    Value Health; 2021 Sep; 24(9):1350-1359. PubMed ID: 34452716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.